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Abstract 
The ultimate therapy for ischemic stroke is restoration of blood supply in the ischemic region and 
regeneration of lost neural cells. This might be achieved by transplanting cells that differentiate into 
vascular or neuronal cell types, or secrete trophic factors that enhance self-renewal, recruitment, long-
term survival and functional integration of endogenous stem/progenitor cells. Experimental stroke 
models have been developed to determine potential beneficial effect of stem/progenitor cell based 
therapies. To follow the fate of grafted cells in vivo, a number of non-invasive imaging approaches 
have been developed. Magnetic Resonance Imaging (MRI) is a high resolution, clinically relevant 
method allowing in vivo monitoring of cells labeled with contrast agents. In this study, labeling 
efficiency of 3 different stem cell populations (mouse Embryonic Stem Cells, rat Multipotent Adult 
Progenitor Cells and mouse Mesenchymal Stem Cells) with three different (ultra) small 
superparamagnetic iron oxide (U)SPIOs particles (Resovist®, Endorem®, Sinerem®) was compared. 
Labeling efficiency with Resovist® and Endorem® differed significantly between the different stem 
cells. Labeling with (U)SPIOs in the range that allows detection of  cells by in vivo MRI, did not affect 
differentiation of stem cells when labeled with concentrations of particles needed for MRI-based 
visualization. Finally, we demonstrated that labeled rMAPC could be detected in vivo and that labeling 
did not interfere with their migration. We conclude that successful use of (U)SPIOs for MRI based 
visualization will require assessment of the optimal (U)SPIO for each individual (stem) cell population 
to ensure the most sensitive detection without associated toxicity. 
 
Keywords: Stem cells, MRI, stroke, iron oxide particles, (U)SPIO, animal models  
 
 
 
 2
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
Introduction 
Neurological disorders such as stroke result in irreversible brain tissue damage for which there is no 
available curative treatment yet. An increasing number of investigators are exploring cell replacement 
approaches to treat neurological disorders, by grafting stem/progenitor cells in animal models 
(6,18,27,29,40,41,43,47,53). Clinically suitable methods are needed to follow the fate of the grafted 
cells in vivo to understand in a temporal manner mechanisms of stem cell survival and functional 
integration (22).  
Due to its noninvasive nature, high contrast in soft tissue and high spatial resolution, Magnetic 
Resonance Imaging (MRI) is one of the most powerful clinical diagnostic tools available today. For 
biomedical applications like cell tracking, grafted cells must be visualized against the background of 
host tissue. Therefore, cells have to be labeled with contrast agents (for review see (7,16,17,30). One 
can use positive contrast agents used in T1-weighted MRI such as lanthanoide-chelates (12) or Mn-
containing compounds (51,52). Alternatively, negative contrast agents, such as superparamagnetic iron 
oxide (SPIO) (4,7,24,31,37,54), ultra small superparamagnetic iron oxide (USPIO) particles 
(4,18,24,31) or micron-sized iron oxide particles (39,46) are highly sensitive and have a dominant 
effect on the T2/ T2* relaxation times, causing negative contrast enhancement in the regions of 
interest. Multiple attributes of these particles determine the labeling efficacy of the agents, including 
the size of the iron oxide particles, the charge and the nature of the coating (for review see (17,30)). 
These physicochemical characteristics not only affect the efficacy of the particles for MRI, but also 
their stability, biodistribution, metabolism and their clearance from the vascular system (11). The 
internalization of (U)SPIOs can be enhanced through pretreatment of these particles with transfection 
agents. The latter are highly charged macromolecules that have been used to transfect DNA into cells 
via electrostatic interaction resulting in endosome formation (2,4,18,24).  
Although labeling of cells has shown to be successful for many applications, very few studies have 
evaluated its effects on cell function (1,23,42,44). The goal of this study was to determine whether 
different stem cell populations being considered for the therapy of neurological disorders, including 
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murine mesenchymal stem cells (mMSC), murine embryonic stem cells (mESC) and rat multipotent 
adult progenitor cells (rMAPC) could be labeled with similar efficiency using different nanoparticles. 
The stability of the labeling after prolonged culture in vitro was also evaluated. In addition, potential 
toxic effects of the labeling on the three stem cell populations were examined. Finally, the possibility 
of in vivo detection of labeled rMAPC was assessed, as well as the effect of the labeling on cell 
distribution when grafted in the setting of photothrombotic lesions. 
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Materials & Methods 
Cell populations 
mMSC from C57Bl/6 mice were obtained from Dr. D Prockop, Tulane University, USA, where they 
were isolated and shown to differentiate into  adipocytes and osteoblasts (33). Isolation and 
characteristics of rMAPC from Fisher rats has been described elsewhere (5).  mESC from 129 mice 
(R1 line) were received from the Vesalius Research Institute (K.U. Leuven, Belgium). All cell lines 
were maintained as described previously (48). Prior to use in our studies, mESC were replated feeder-
free on 0.1% gelatin (Chemicon, Billerica, USA) coated plates.  
Cell labeling 
The following magnetic resonance iron-based contrast agents were used: Resovist® (particle diameter 
60nm), (Shering, Munchen, Germany), Sinerem® (particle diameter 20-40nm) and Endorem® (particle 
diameter 80-150nm) (both Guerbet, Roissy, France). Cell labeling was performed by co-culture of the 
cells with (U)SPIOs with and without transfection agents (23kDa or 388 kDa Poly-L-lysine) for 4 to 
24hrs. The concentration of (U)SPIOs was tested in a range of 20 to 500g total iron per ml of culture 
medium. Final concentrations used were Resovist®: 50µg/ml; Endorem®: 348µg/ml; Sinerem®: 
500µg/ml.   
Iron quantification 
Cell pellets of labeled and unlabeled cells were collected 24hrs, 48hrs and 72hrs after labeling and 
mineralized ‘au bain marie’ prior to Induced Coupled Plasma-Mass Spectroscopy (ICp-MS) (Perkin 
Elmer, Massachussetts, USA). Values per tube were calculated as follows: total iron content per pellet 
= µg total iron per liter x (mass mineralized BM/density mineralized BM) x dilution (according to 
Guerbet protocol).  
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Dextran staining 
Cells were fixed with 10% NBF (60% PBS and 40% formaldehyde (Sigma, St Louis, USA)) for 15 
min, washed and incubated for 15min with PBS (Sigma) + 0.1% Triton (Sigma). Next, cells were 
rinsed and stained with mouse anti-dextran-FITC (1:1000, Stem Cell Technologies, Vancouver, 
Canada) overnight. The next day, cells were rinsed and staining was detected using fluorescent 
microscope (AxioImager, Zeiss, Gottingen, Germany). 
Cell proliferation 
Labeled cells were cultured in their specific expansion medium under standard conditions (48). Cells 
were counted each day using a nucleocounter. Population doubling time (PDT) was calculated as 
follows: T x Ln2 / Ln(A/A0), with T = time between two cell counts, A= the number of cells at end, 
A0= the initial number of cells. We followed the PDT of the labeled cell populations for 7days.  
Cell differentiation assays 
Differentiation of mMSC to the osteogenic and adipogenic lineage was performed according to 
standardized methods (13,14,35). Differentiation of rMAPC to the endothelial, neuroectodermal and 
hepatic lineage was performed as described in (48).  
In vitro osteogenic assays: Unlabeled and (U)SPIO labeled mMSC were seeded at 104 cells/cm² in 24-
well plates.  After 2 days in culture, the medium was replaced by osteogenic medium [expansion 
medium supplemented with 100nM dexamethasone, 10mM beta-glycerophosphate  and 50µM 
ascorbic acid 2-sulfate (Sigma)] for 3 weeks (25). The cells were lysed in 150µl PBS containing 
0.05% Triton X 100 (Sigma). Alkaline phosphatase activity was measured using a commercially 
available kit (Kirkegaard & Perry, Guildford, UK), according to the manufacturer’s instructions. DNA 
content was determined with the Quant-iT™ dsDNA HS Assay (Invitrogen). Parallel samples were 
processed for RNA extraction at 6 and 14 days. After 3 weeks of treatment with osteogenic medium, 
calcium deposits were stained with alizarin red. After taking pictures with a Nikon Coolpix 995 
camera through an inverted microscope (Telaval 31, Zeiss), alizarin red was extracted as described 
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previously and absorbance was measured at 492nm. Unlabeled bone marrow-derived cells (hBMDCs) 
were used as positive control.  
In vitro adipogenesis: Unlabeled and (U)SPIO labeled mMSC were seeded in 24 well plates at a cell 
density of 104 cells/cm². Cells were allowed to become confluent in expansion medium. Adipogenic 
induction medium was then added, consisting of expansion medium supplemented with 1µM 
dexamethasone, 0.5mM methyl-isobutylxanthine, 10µg/ml insulin, and 100mM indomethacin (all 
from Sigma). After 72 hrs, the medium was changed to adipogenic maintenance medium (10µg/ml 
insulin in culture medium) for 24 hrs. Cells were treated 4 times with induction medium. The cells 
were then maintained in adipogenic maintenance medium for 1 week before fixation. After 21 days 
cells were washed twice with PBS, fixed with 0.2% glutaraldehyde (Sigma) for 5 min, washed with 
PBS, rinsed in 60% isopropanol, and covered with oil red O solution (0.1% oil red O [Sigma] in 60% 
isopropanol). After 10 min, cultures were briefly rinsed in 60% isopropanol, washed thoroughly in 
distilled water, and counterstained with hematoxylin. 
Differentiation of MAPC to the endothelial, neuroectodermal and hepatic lineage was performed as 
described in Ulloa-Montoya et al. (48). 
Briefly, for endothelial differentiation, rMAPC were plated in fibronectin-coated wells. On day 1, 
medium was switched to a differentiation medium (low glucose DMEM/MCDB-201 (60:40) 
containing 10ng/ml hVEFG-A (R&D Systems), 1X ITS, 1X LA-BSA, 10-8M dexamethasone, 10-4M 
ascorbic acid 3-phosphate, 100 units of penicillin, 1,000 units of streptomycin and 55M 2-
mercaptoethanol (Cellgro). RNA samples were collected on day 9 for analysis.  
For hepatic differentiation, rMAPC  were plated in matrigel coated wells in low glucose 
DMEM/MCDB-201 (60:40) containing 2% FBS, 0.25X ITS, 0.5X LA-BSA, 0.1x10-6M 
dexamethasone, 10-4M ascorbic acid 3-phosphate, 100 units of penicillin, 1,000 units of streptomycin 
and 55 M 2-mercaptoethanol. The following cytokines were added sequentially: 100ng/mL Activin-
A and 50ng/mL BMP4; 10ng/ml FGF2 and 25ng/mL FGF8b; and 20ng/m HGF and 10ng/ml 
Oncostatin-M (all from R&D systems). RNA samples were collected on day 20 for analysis.  
 7
155 
156 
157 
158 
159 
160 
161 
162 
163 
164 
165 
166 
167 
168 
169 
170 
171 
172 
173 
174 
175 
176 
177 
178 
179 
180 
For neuroectoderm differentiation, MAPC were plated on gelatin coated T75 flasks in N2B27 
medium (DMEM-F12:NeurobasalA medium (Invitrogen) 1:1 supplemented with N2 supplement (1x, 
R&D) and B27 (1x, Invitrogen), 100 units of penicillin, 1,000 units of streptomycin, 55M 2-
mercaptoethanol and 200nM L-glutamine (Invitrogen). After 2 days medium was changed to NSE 
medium (Euromed medium (Euroclone) supplemented with N2 supplement (1x, R&D), 200nM L-
glutamine (Invitrogen), 100 units of penicillin, 1,000 units of streptomycin and bFGF (10ng/ml, 
R&D) and EGF (10ng/ml, R&D).   RNA samples were collected on day 6 for analysis. 
RT-qPCR 
Experiments were conducted as described (48). For rMAPC and mESC, total RNA from 
undifferentiated and differentiated cells was extracted using the RNAeasy microkit (Qiagen, Valencia, 
CA). cDNA was generated by reverse transcription using Superscript III ReverseTranscriptase 
(Invitrogen, Carlsbad, USA). To test the expression of gene(s) of interest a real-time PCR was 
performed as follows: 40 cycles of a two step PCR (95°C for 15”, 60°C for 45”) after initial 
denaturation (95°C for 10’) with 2µl of cDNA solution, 2X SYBR Green Universal Mix PCR reaction 
buffer (Invitrogen). Expression of target genes was normalized to Gapdh. Gene expression level 
represented as Delta CT: Delta CT (CTgene of interest – CTGAPDH). Primers used for amplification:  
rOct 4   (f: CTGTAACCGGCGCCAGAA, r: TGCATGGGAGAGCCCAGA); 
rSox2   (f:AACCCCAAGATGCACAACTC, r:CCGGGAAGCGTGTACTTATC);  
rPax6   (f:GTCCATCTTTGCTTGGGAAA, r:TAGCCAGGTTGCGAAGAACT);  
rVimentin  (f: AATGCTTCTCTGGCACGTCT,r: GCTCCTGGATCTCTTCATCG);  
rEn1   (f: CAGAGACTCAAGGCGGAGTT,r: CCTGTGGCTTTCTTGATCTTG);  
rvWF   (f: CCCACCGGATGGCTAGGTATT,r: GAGGCGGATCTGTTTGAGGTT);  
rFlk1   (f: CCAAGCTCAGCACACAAAAA,r: CCAACCACTCTGGGAACTGT);  
rPecam  (f: GGACTGGCCCTGTCACGTT,r: TTGTTCATGGTGCCAAAACACT);  
rProx1   (f: GGAGATGGCTGAGAACAAGC,r: AGACTTTGACCACCGTGTCC); 
rAfp  (f: ACCTGACAGGGAAGATGGTG,r: GCAGTGGTTGATACCGGAGT); 
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rG6P  (f: AACCTGGTAGCCCTGTCTTT,r: GGGCTTTCTCTTCTGTGTCG);  
rAlb   (f: TCTGCACACTCCCAGACAAG,r: AGTCACCCATCACCGTCTTC);  
rTat   (f: AACCTCAGCACCAATGTTCC,r: TCTTCAGAGCACCCTGGACT)  
r/mGapdh (f: TGCCACTCAGAAGACTGTGG, r: GGATGCAGGGATGATGTTCT); 
mOct4  (f: CCAATCAGCTTGGGCTAGAG, r: CCTGGGAAAGGTGTCCTGTA) 
  
For osteogenic and adipogenic differentiation studies, cells and cell pellets obtained in the in vitro 
differentiation experiments were homogenized in a cell lysis buffer from the RNA-extraction kit 
(Nucleospin, BD Biosciences). RNA extraction was performed according to manufacturer’s 
recommendations. Complementary DNA (cDNA) was obtained by reverse transcription of 1µg of total 
RNA with Oligo (dT)20 as primer (RevertAid™ H Minus First Strand cDNA Synthesis Kit; 
Fermentas Life Sciences). To evaluate gene expression, taqman PCR was performed on Corbett 6000 
Rotorgene system (Westburg) using the assay-on-demand probes from Applied Biosystems. (Assay 
numbers: GAPDH: 4352339E ALP: Mm01187117_m1, iBSP: Mm00492555_m1) cDNA obtained 
from expanded mBMCs before labeling and treatment was used as a reference sample. Gene 
expression levels are listed as Delta CT: delta CT (CTgene of interest – CTGAPDH). 
Electron microscopy 
Cells were fixed with 3.5 % glutaraldehyde (Electron microscopy Science, Hatfield, USA) for 1hr at 
37 ºC. Cells were post-fixed with 1% osmiumtetroxide (Sigma), rinsed, dehydrated and embedded in 
araldite (Durcupan, Sigma). Semithin sections (1.5µm) were cut with a diamond knife and stained 
lightly with 1% toluidine blue (Panreac, Barcelona, Spain). Semithin sections were re-embedded in an 
araldite block and detached from the glass slide by repeated freezing (liquid nitrogen) and thawing. 
The block with semi-thin sections was cut in ultra-thin (0.05µm) sections with a diamond knife, 
stained with lead citrate and examined under a Tecnai spirit electron microscopy (FEI). Photographic 
images were taken with a Morada camera (Soft Image System, Munster, Germany). For (U)SPIOs 
particle quantifications an average of 5 ultra-thin sections corresponding to different locations were 
analyzed for every time point and the quantification was carried out by three independent scientists. 
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FACS (fluorescence-activated cell sorting) 
FACS staining was performed as described (48). Unlabeled and (U)SPIO labeled cells were collected 
by trypsinization, washed  with  PBS (Invitrogen) containing 3% FBS and blocked for 10 min with 5% 
rat serum (Jackson ImmunoResearch, West Grove, USA) and 10µl anti CD16/CD32 (2.4G2) antibody 
(BD bioscience).  After  washing,  cells  were  incubated  for  30  min  at  4oC  in  3%  FBS  containing 
conjugated  antibodies. Cells were washed once and resuspended in PBS 3% FBS and analyzed by 
flow cytometry on FACSCanto (BDPharmingen, San Jose USA). Antibodies used to characterize 
rMAPC were anti-CD44-FITC (OX-49) and antiCD31-PE (TLD-3A12). Mouse IgG2a,  (G155-178) 
and mouse IgG1, (MOPC-31C) are respectively used as isotype controls. For mMSC anti-CD44-
APC (IM7) and anti-ckit-PE (2B8) were used and rat IgG2b, (A95-1) was used as isotype control (all 
antibodies were from BDPharmingen, San Diego, CA).  
Cytogenetics  
Evaluation of cell ploidy was performed as described (48). Demecolcine (10µg/ml in HBSS -
Invitrogen) was added to the media until 50% of the cells were detached. Media was removed and the 
remaining attached cells were collected following rinsing. Cells were centrifuged at 1000 RPM for 5 
min, and the pellet transferred to a conical tube with PBS. 0.0075M KCl was added, pre-warmed to 
37°C. After 10min, cells were centrifuged and the pellet mixed with fixative. Cell suspensions were 
dropped on the slide and allowed to dry. Slides were stained with 1:5 diluted Wright-Giemsa stain 
(0.4% w/v in MeOH) in Gurr Buffer (Gibco). The number of chromosomes per cell was enumerated 
for at least 40 cells under a light microscope (Zeiss).   
Photothrombotic animal model and cell injections 
Animal experiments were approved by the bioethics committee of K.U.Leuven (P06098, Leuven, 
Belgium). Male and female NOD-SCID/gamma c-/- mice were obtained from the breeding colony in 
the SPF facility at K.U.Leuven. Male Fisher 344 rats were purchased from Charles River, Wilmington, 
USA. All animals were housed with access to food and water. For surgery, 3-week-old mice or 8-
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week-old rats were anesthetized intraperitoneally with ketamine (Ketamine 1000, 75 mg/kg;CEVA 
Santé Animale, Libourne, France) and medetomidin (Domitor, 1 mg/kg; Orion Pharma, Espoo, 
Finland). 
Cortical photothrombosis was induced in 8 mice and 8 rats. A vertical incision was made between the 
right orbit and the external auditory canal. The upper part of the temporalis muscle was cauterized so 
that the muscle could be displaced. Photoillumination with green light (wave length, 540nm; 
bandwith, 80nm) was achieved using a Xenon lamp (model L-4887; Hamamatsu Photonics, 
Hamamatsu City, Japan) with heat-absorbing and green filters. The irradiation at intensity of 
0.68W/cm2 was directed with a 3mm optic fiber, which was placed on the exposed skin above the 
Midlle Cerebral Artery. Photoillumination was performed for 20min after intravenous injection of the 
photosensitizer Rose Bengal (20mg/kg, Sigma-Aldrich) in a tail vein. Control experiments were 
performed without injection of the photosensitizer. No photothrombotic injury was detected in control 
animals. 
Injection of GFP+ MAPC was performed in 8 control mice to establish detectability thresholds and 
also in 8 rats 2 days after photothrombosis. The head of the animals was positioned in a stereotactic 
head frame (Stoelting, Wood Dale, IL) for stereotactic injection into the striatum. The skull was 
exposed by a small midline incision and a hole was drilled into the skull in the appropriate location, 
using bregma as the reference point. Stereotactic coordinates starting from the dura were as follows: 
Lateral +0.20cm for left injection, -0.20cm for right injection; Anterior-posterior +0.05cm; depth 3mm 
to 2mm (mice). Lateral +0.28 cm for left injection, -0.28 cm for right injection; Anterior-posterior 0.11 
cm; depth 4mm (rat).  Using a 30-gauge Hamilton syringe (VWR International, Haasrode, Belgium), 
10,000 or 50,000 labeled cells were injected in mice or 10,000 or 1,000,000 cells were injected in rat 
at a rate of 0.25µl/min into left or right striatum, respectively. After injection, the needle was left in 
place for an additional 5min before slowly withdrawn. Anesthesia was reversed with atipamezol 
(Antisedan, 0.5mg/kg; Orion Pharma), administered intraperitoneally.  
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In vitro MRI experiments of labeled cells 
For the assessment of the in vitro visualization of (U)SPIO labeled cells by MRI, phantoms were built 
using culture dishes (3.5cm diameter) filled with agar (Sigma-Aldrich, 0.8 % in saline). Drill holes 
(4mm diameter of a defined depth) were filled with cell suspensions of known concentration. After 
solidification of the cell-agar suspensions, drill holes were closed with additional agar. All MR images 
were acquired using a Bruker Biospec 9.4 Tesla small animal MR scanner (Bruker Biospin, Ettlingen, 
Germany; horizontal bore, 20cm) equipped with actively shielded gradients (600mT m-1). A purpose-
built radio-frequency solenoid transmit-receive coil with a length of 6cm and an inner diameter of 4cm 
was used for all phantom experiments. 2D multi-slice-multi-echo (MSME) experiments were acquired 
for the calculation of T2-maps (TR=6,000ms and 10 TE increments of 10ms, 2562 matrix, 156 x 156 
µm in plane resolution, 0.8mm slice thickness). T2* maps were acquired similarly to MSME 
experiments using a gradient echo pulse sequence and 10 TE increments of 4.5ms. Three-dimensional 
(3D), high-resolution T2*- weighted MR images were acquired using a gradient echo sequence 
(FLASH, TR=200 ms, TE=15 ms, flip angle 30°). The field-of-view was 3.8 x 3.8 x 0.75cm. The 
resolution was usually 74 x 74 x 59µm. 
 
In vivo MRI experiments 
MR images from animals were usually acquired within 12hrs after photothrombosis. Subsequent 
images were acquired within 12hrs after cell engraftment and were repeated for up to 10 days after 
implantation. MR images were acquired using an actively decoupled linear polarized RF resonator as 
transmitter (inner diameter 7cm, Bruker Biospin) with respective mouse and rat brain surface coils 
(Bruker Biospin) as receiver. After acquisition of 2D multislice localizer images, 2D MSME 
experiments were acquired for the calculation of T2-maps (TR=6,000ms and 10 TE increments of 
10ms, 2562 matrix, 156 x 156 µm in plane resolution, 0.8mm slice thickness). High resolution 3D 
FLASH images were acquired for the visualization of labeled cells thereafter resulting in an isotropic 
spatial resolution of 100µm3. Other acquisition parameters were TR = 100ms, TE = 12ms, flip angle 
30°. Diffusion-weighted MR images (spin echo) were acquired for the first two time points after the 
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2, 1mm slice thickness. 
 
MRI data processing 
Images were processed using Paravision 4 (Bruker Biospin) and NIH ImageJ. Relaxation rates (r2) 
were determined as mean values of homogeneous sections of the cell loaded areas in the agar 
phantoms. Values were compared to those of unlabeled cells in the same phantom. Relative 
quantification was also performed using 3D T2*-weighted MR images. The relative mean signal 
intensity of the respective drill holes was determined relative to unlabeled cells (SI=100%). Data were 
expressed as mean ± SD.  
Immunohistochemistry 
Animals were sacrificed at 1,5 or 3 weeks after injection with an intraperitoneal overdose (300µl/20g ) 
of pentobarbital (Nembutal; CEVA Santé Animale) and transcardially perfused with 4% (w/v) 
paraformaldehyde (PFA, Sigma) in PBS. Brains were removed and postfixed overnight in 4% PFA. 
Serial 50µm coronal sections were made with a microtome (Vibratome, St. Louis, MO). Hematoxylin/ 
eosin staining was performed for all brains to assess injury. GFP staining was performed for 
visualization of transplanted cells (1:30, Clonetech, CA, USA).  
Statistical analysis 
For in vitro experiments student’s paired two-tailed t test was used for comparison of 2 experimental 
groups. Changes were identified as significant if p<0.05. When multiple groups were compared, 
Bonferroni correction was applied. Data are shown as mean +/- standard deviation. 
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Results 
Labeling efficiency of mMSC, rMAPC and mESC with Resovist®, Sinerem® and Endorem®  
In initial experiments, we tested the optimal time for labeling and whether addition of transfection 
agents was needed for labeling with Resovist®, Sinerem® and Endorem®. Greater amounts of 
(U)SPIOs were taken up by cells incubated for 24hrs with either Resovist®, Sinerem® and Endorem® 
compared to incubation for 4hrs (microscopy after Prussian Blue staining). Hence all subsequent 
studies were done by incubating cells 24hrs. Particle clustering was observed when 23kDa poly-L-
lysine (PLL) instead of 388kDa PLL was used as transfection agent together with Resovist®. Hence, 
all further experiments were performed using 388kDa PLL. Comparison of (U)SPIOs uptake with and 
without the transfection agent (PLL) showed that Resovist® and Sinerem® were taken up (more 
efficiently) in the presence of PLL compared with uptake experiments without the transfection agent. 
However, uptake of Endorem® was not affected by the presence or absence of PLL (data not shown). 
Optimal labeling was defined as being able to detect the lowest cell density (15 cells/l) for one of the 
three stem cell populations by MRI of phantoms containing labeled cells. After testing various 
(U)SPIO concentrations and incubation times, this was achieved using the following conditions: 
50µg/ml Resovist® combined with 0.75µg/ml Poly-L-Lysine (388 kDa), 500µg/ml Sinerem® 
combined with 0.75µg/ml Poly-L-Lysine (388 kDa), and 348µg/ml Endorem® without transfection 
agent for 24hrs (data not shown).  
The size, amount, density and localization of (U)SPIO inclusions in the cells was evaluated by 
transmission electron microscopy (TEM). As shown in Table 1, the number of inclusions per rMAPC 
was significantly higher for Sinerem® compared to Endorem® and Resovist®. The average size of 
inclusions, representing clustered (U)SPIOs, was  significantly higher for Resovist® and Sinerem® 
when compared to Endorem®. The density of inclusions was significantly higher for Endorem® and 
Resovist® compared with Sinerem®. The quantity of internalized iron per cell was evaluated by ICP-
MS as shown for time points day1, day2 and day3 after labeling for 24hrs (Fig. 1ABC). When 
different particles were compared within one cell population, higher concentrations of iron were 
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detected in rMAPC and mMSC labeled with Resovist® (2.51 and 11.58pg/cell respectively) at day 1, 
while in mESC the highest concentration of iron was found following labeling with Endorem
336 
337 
338 
339 
340 
341 
342 
343 
344 
345 
346 
347 
348 
349 
350 
351 
352 
353 
354 
355 
356 
357 
358 
359 
360 
361 
® 
(4.14pg/cell) at day 1. In general, the most iron was in average detected in mMSC, most likely due to 
their larger size (surface area measured by TEM: mMSC 363.61+/-267.76µm²; rMAPC 157.81+/-
89.93µm² and mESC 114.54+/-61.48µm²).  
The quantity of iron per rMAPC decreased significantly at day3 (fold decrease of 3.9 for Resovist®, 
5.3 for Endorem® and 4.25 for Sinerem®). In mESC there was significant decrease of iron for 
Resovist® by day3 (fold decrease 2.1) and for Sinerem® by day2 (fold decrease 1.4). In contrast, no 
reduction could be observed in mMSC (see Fig. 1). The number of inclusions over time was also 
evaluated. As expected, in all three stem cell types, the number of inclusions decreased over time (Fig 
1DEF).  
In vitro evaluation of cell labeling by MRI 
Visualization of stem cells by MRI is only successful if the amount of (U)SPIOs taken up is sufficient 
to alter contrast in MRI. To determine if sufficient particles were present in cells to be visualized by 
MRI, we made agar phantoms containing different numbers of labeled cells to determine the minimum 
detectable cell number. To assess the effect of dilution of intracellular (U)SPIOs due to cell 
proliferation and its influence on cell detectability, phantoms containing cells were scanned 24hrs, 
48hrs and 72hrs after labeling. Figure 2 shows 3D T2* weighted MRI as well as T2- and T2*-maps of 
cell phantoms. Cell densities as low as 5 cells/µl were detectable for cells labeled with Endorem® 
(mESC, rMAPC, mMSC) or Resovist® (rMAPC, mMSC). Labeling with Sinerem® resulted in less 
contrast resulting in a detectability limit in the order of 75cells/µl. The MRI contrast strongly 
depended on the combination of stem cell type and contrast agent. Resovist® was superior over 
Endorem® for rMAPC and for mMSC labeling. However, labeling of mESC was most efficient using 
Endorem® compared to Resovist® (Fig. 2A). Moreover, contrast in T2*-weighted MRI was more 
pronounced in the larger mMSC for all particles compared to mESC and rMAPC. Absolute 
quantification of cell numbers was not possible due to large magnetic susceptibility effects of the 
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labeled cells at high densities. Fitting for T2- and T2*-maps was not possible due to signal quench 
even for the lowest echo times. Counting of erased pixel clusters in 3D T2*-weighted MR images of 
cell suspensions of low density (as described by Kustermann et al. (24)) did not yield a correlation 
with cell numbers due to cell clustering. 
When cells were cultured for 48hrs in iron free medium prior to MRI, decreased detectability of 
labeled cells was observed (Fig. 2B). Consistent with experiments immediately after cell labeling (Fig. 
2A), sensitivity of MRI detection strongly depended on the combination of stem cell type and 
(U)SPIO. In line with the results of iron uptake (Fig. 1), Endorem® was more efficient for mESC 
labeling whereas Resovist® resulted in better detectability of rMAPC and mMSC. The lower 
proliferation rates of mMSC compared to rMAPC and mESC resulted in less dilution of the contrast 
agents with time and similar detectability thresholds after additional 72hrs incubation in iron free 
medium (data not shown).  
Effect of labeling on stem cell proliferation, phenotype and genetic integrity 
We evaluated whether labeling of mMSC, rMAPC and mESC with either (U)SPIO affects cell 
proliferation over a period of 7 days. Results are shown in Fig 3. Labeling of mMSC with Sinerem® 
resulted in an increased PDT on d5, compared with unlabeled cells or cells labeled with Endorem® and 
Resovist®. However by day 7, no significant differences were noted between mMSC labeled with any 
of the contrast agents compared with unlabeled mMSC (Fig. 3A). Labeling with any of the contrast 
agents did not affect mESC PDT over the 7 day period (Fig. 3B). By contrast, labeling of rMAPC with 
either Sinerem® or Endorem® resulted in a lengthening of the PDT on d5, which was statistically 
significant compared to cells labeled with Resovist® or unlabeled cells (Fig. 3C). The phenotype of 
mMSC, rMAPC and mESC was validated following labeling with the different (U)SPIOs. mESC 
represent pluripotent stem cells (21), characterized by the expression of key transcription factors that 
maintain the pluripotent state. Among these is the Pou5f1 transcription factor, also known as Oct4 
(32). We determined the transcript levels of Oct4 in mESC 2 days after labeling with the (U)SPIOs. In 
Resovist® labeled mESC, the level of Oct4 transcripts was 2.77 fold higher compared to control, 
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although this was not statistically significant (Fig. 4A). We have previously shown that, similar to 
mESC but in contrast to mMSC, rMAPC also express Oct4, and that presence of Oct4 is associated 
with the significantly broader differentiation potential of rMAPC (48). Therefore, the expression of 
Oct4 was also evaluated in rMAPC 2 days after labeling with (U)SPIOs and in unlabeled controls. As 
for mESC, we could not detect a statistically significant difference in Oct4 transcript levels in rMAPC 
labeled with any of the (U)SPIOs compared to unlabeled rMAPC (Fig. 4B). 
We and others have shown that mMSC, used in the present study, express among others the cell 
surface anitgen CD44 at high levels, but not c-kit (33,47). rMAPC are CD44dim/CD31+  (5,48). To 
ascertain that labeling with (U)SPIOs did not affect the mMSC and rMAPC cell identity, we evaluated 
cells 3 days after labeling with the 3 contrast agents by FACS. No obvious changes in cell surface 
phenotype were identified following labeling (Fig 4CD). 
We also assessed whether labeling with any of the (U)SPIOs would cause increased aneuploidy of 
mMSC, rMAPC or mESC. It should be noted that previous published studies have shown that mMSC 
become aneuploid very quickly after isolation, including the mMSC population used here (19). 
Compared to unlabeled control cells, the ploidy of labeled cells was not decreased for up to five days 
after labeling (rMAPC: 72.17% +/- 3.50; mESC: 50.9% +/- 8.82; mMSC: 3.3% +/- 0.01).  
Effect of labeling on stem cell differentiation 
Previous reports suggested that labeling of stem cells, such as mMSC, with (U)SPIOs may affect their 
differentiation ability (23). We therefore tested the effect of (U)SPIO-labeling on the differentiation 
ability of mMSC and rMAPC (Fig. 5).  
mMSC differentiate towards osteoblasts and adipocytes (33,35,36). Treatment with dexamethasone, 
beta-glycerophosphate and L-ascorbic acid, to induce osteogenic differentiation resulted in a similar 
increase in alkaline phosphatase (Fig.5A), and calcium deposition by day 14 when labeled and 
unlabeled mMSC were compared. Statistically significant increases in transcripts for the osteogenic 
markers, Alp (26) and Bsp (15), were similar in labeled and unlabeled cells on day 14 of osteogenic 
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differentiation (Fig. 5B). Adipogenic differentiation was induced using insulin and assessed by Oil 
Red O staining (Fig. 5C). Cells stained with Oil Red O were similar in labeled or unlabeled cells, for 
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®-labeled cells a modest decrease in staining is seen based on visual observations. Hence, 
labeling of mMSC with Resovist®, Sinerem® or Endorem® did not affect the differentiation ability of 
mMSC towards osteoblasts and adipocytes. As shown in Fig. 5I-N, TEM demonstrated persistent 
presence of the different (U)SPIOs in the differentiated mMSC progeny over the whole time period of 
the experiment.  
In comparison with mMSC, rMAPC have significantly broader differentiation ability, and can 
generate progeny of the three germ layers (48). To assess the effect of (U)SPIO labeling on rMAPC 
differentiation, differentiation to hepatocyte-, endothelium- and neuroectodermal progenitor-like cells 
was induced using methods described previously (48). Lineage differentiation was assessed by RT-
qPCR for lineage specific gene transcripts (Fig. 5DEF). Differentiation towards hepatocyte-like cells 
was induced using a multistep protocol as described (48). For labeled or unlabeled cell populations, a 
similar increase in transcripts for alpha-fetoprotein (Afp) (9), albumin (Alb) as well as the mature 
hepatocyte gene Tat (8)  was seen by day 21 (Fig. 5D). Differentiation to endothelium of rMAPC 
labeled with (U)SPIOs and unlabeled controls was induced with VEGF-A. A similar induction of 
Flk1, Prox1 and Pecam (20) was observed Fig. 5E. Differentiation of rMAPC towards 
neuroectodermal progenitor cells was achieved using a protocol based on studies by Conti et al. (10) 
and described in Ulloa et al. (48). A similar increased expression of transcripts for Sox2 and Pax6 (50) 
was found in labeled and unlabeled cells (Fig. 5F). 
Samples from differentiated rMAPC-progeny were fixed and analyzed under TEM. rMAPC-derived 
hepatocytic and endothelial progeny continued to contain (U)SPIOs in, respectively, 20% and 100% of 
the cells (Fig. 5GH). 
In vivo tracking of labeled cells in the brain  
As proof of principle for in vivo cell visualization, rMAPC labeled with Resovist® were 
stereotactically engrafted into the striatum of NOD-SCID γ c -/- mice. 10,000 and 50,000 rMAPC 
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suspended in 2µl PBS were injected in the left and right hemisphere respectively. Animals were 
monitored repeatedly by MRI for three weeks. As shown in Fig. 6A-B, 10,000 cells could be 
visualized in 3D T2* MR images. The contrast and the hypointense volume of the implanted cells in 
MRI remained constant over the observation period (data not shown). Control injections with PBS or 
unlabeled cells did not change contrast apart from injuries due to the surgical procedure (needle track). 
Location of cells in the MRI was confirmed by histology (Fig. 6C).  
As also confirmed by MRI, rMAPC were injected 1-3 mm from a photothrombotic lesion. Cells were 
found along the corpus callosum towards the infarct region within 24hrs. However, no infiltration of 
rMAPC into the lesion area was seen (Fig. 6D).  
Experiments were repeated in eight-week-old Fisher rats with a phototrombotic injury (Fig. 7). 
Resovist®-labeled rMAPC were injected close to the lesion 24hrs after photothrombosis. 
Combinations of 100,000 labeled (Resovist®) GFP+ rMAPC with or without 900,000 unlabeled 
rMAPC were injected in the brain 2 to 8mm from the photothrombotic injury localized in the cortex of 
male Fisher rats (n=8). Cell relocation into less dense brain tissue such as the Corpus Callosum and the 
stroke region or along the needle tract was visualized by MRI (Fig. 7C). Localization of the cells was 
confirmed with GFP staining and Hematoxylin-eosin staining (Fig. 7DE). Unlabeled control cells 
showed a similar distribution pattern suggesting that labeling does not appear to affect the 
redistribution of rMAPC in vivo (Fig. 7B and data not shown). When mMSC were implanted, no 
redistribution of the cells along the corpus callosum was found (Fig. 7A). 
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Discussion  
Non-invasive imaging plays an important role in stem cell research because it allows following an 
individual animal over time and studying the temporal behavior of endogenous or transplanted stem 
cells. One of the most clinically relevant imaging modality is MRI, because of its high spacial 
resolution in comparison with for instance PET, and the possibility to label cells without the need for 
genetic manipulation that is needed to introduce other markers such as fluorochromes in cells.  
For many applications, contrast agents like highly sensitive (U)SPIOs  are used for negative contrast 
enhancement (4,7,18,31,39,46,54). Due to their physicochemical characteristics, label uptake and 
stability of the particles in cells differs between different types of (U)SPIOs (2,4,18). In addition, some 
reports have suggested that (U)SPIO labeling may affect certain biological properties of cells 
(24,28,38,45). However, only limited data exist on the comparison of labeling efficiency and possible 
toxicity of the particles on different stem/progenitor cell populations. In this study, cell labeling 
efficiency of three stem cell populations, mMSC, rMAPC and mESC with three (U)SPIOs (Resovist®, 
Endorem® and Sinerem®) was compared, and potential adverse effects of different labeling procedures 
on the biology of the cells was examined. 
Two of the three particles tested, Resovist® and Sinerem®, are taken up better by the stem/progenitor 
cells when PLL 388kDa is added, whereas uptake of Endorem® is not further enhanced when a 
transfection agent is added to the particle. Our study also demonstrates that different amounts of iron 
in the culture medium are necessary for the three (U)SPIO to visualize the cells by MRI. Also, the 
labeling efficiency with three different (U)SPIOs varies significantly when different stem cell 
populations are compared. This was shown by a combination of techniques, including dextran staining 
(for Endorem® and Sinerem®), measurement of intra-cellular iron by ICP-MS, electronmicroscopy 
which also demonstrated that the number and distribution of iron particle inclusions within cells 
differed for the various (U)SPIOs . These findings were also confirmed by in vitro MRI, which 
reflected the data from ICP-MS. Comparison of electron microscopy with iron quantification (ICP-
MS) and MRI indicates that the size and density of occlusions but not the number of occlusions 
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correlates with the internalized amount of iron and MRI contrast. The small size of Sinerem® results in 
a larger number of small inclusions that are less dense and therefore contain less iron compared to 
Endorem
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® and Resovist®. These results demonstrate that labeling methods will likely need to be 
optimized for every cell type that is used. Over time, we saw a decrease of iron in the cells. This is 
mainly due to dilution of (U)SPIOs with cell division but might also occur due to exocytosis of the 
particles (24).  The PDT of mESC and rMAPC is 12hrs, whereas the PDT for mMSC is 48hrs, which 
explains the significant reduction of iron in rMAPC. However, as this is not observed in mESC, 
further studies on exocytosis are needed to evaluate the loss of iron. In this study, two cell populations 
were from murine origin and one from rat. Whether the species origin plays a role in the efficiency of 
stem cell labeling is not known. Also not known is the mechanism(s) underlying the differences in 
labeling efficiency between cell types. 
The second major goal of this study was to evaluate whether (U)SPIO labeling affects the biology of 
cells, as at least some studies suggested that labeling of mMSC affects differentiation potential 
(24,37). No significant alterations were observed in the cell phenotype of mMSC, rMAPC and mESC 
following labeling, whereas differentiation ability of mMSC or rMAPC remained unchanged. For 
rMAPC progeny committed to an endothelial and hepatocytic phenotype, the labeling persisted until 
final differentiation of these cells, demonstrating that the label does not significantly affect stem cell 
differentiation. However, neural progeny contained few remaining SPIOs, likely due to extensive 
proliferation occurring during the generation of NSC-like cells from rMAPC. Hence, no images are 
shown from this experiment. Similarly, labeling persisted in mMSC differentiated to the adipocyte and 
osteocyte lineage, without influencing the differentiation process. It should be noted, however, that 
Sinerem® decreased proliferation of mMSC, and both Sinerem® and Endorem® affected the 
proliferation of rMAPC, even though prolonged culture (until 7 days) resulted in restoration of the 
proliferation rate. Large numbers of endosomal inclusions might thus affect the proliferation capacity 
of mMSC and rMAPC. This may particularly be true for rMAPC as the number of inclusions was 
significantly higher during the initial days of culture, but decreased substantially when rMAPC were 
maintained in culture which correlated with a restoration of the proliferation rate. One should also note 
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that higher concentrations of Sinerem® and Endorem® were neccessary for cell labeling to achieve a 
similar MRI detectability . Although the ploidy of cells was evaluated, and no effect of cell labeling 
was found, more detailed genotoxicity studies still need to be performed. As no spectral karyotyping 
or comparative genomic hybridization was performed, we cannot fully ascertain that labeling with 
(U)SPIO was not genotoxic. As TEM demonstrated that the (U)SPIOs are located nearly exclusively 
in the cell cytoplasm, genotoxicity is however unlikely.   
Finally, we evaluated for rMAPC whether cells labeled with Resovist®, that was taken up the best in 
rMAPC and provided the most sensitive labeling in phantoms in vitro, can also be monitored by MRI 
following transplantation in vivo. When grafted in either mouse or rat brain, with or without stroke, 
labeled rMAPC were visualized until 15 days after transplantation. In the absence of brain injury, no 
clear migration of the particles was observed. When grafted in animals that previously underwent 
photothrombotic stroke, some migration of cells was seen. However, whether this was spontaneous 
migration along the less dense brain tissue in the Corpus Callosum or directed migration towards the 
stroke region is still being examined. That the labeled rMAPC did not migrate into the lesion, may be 
due to the creation of scar tissue around the photothrombotic ischemic lesion (3). As unlabeled cells 
showed the same pattern, these studies demonstrate that cell labeling does not affect the ability of stem 
/ progenitor cells to migrate in vivo.  
In conclusion, our study highlights that it is necessary to evaluate the efficiency of cell labeling for 
every new cell-contrast agent combination whose fate is being followed in vivo. Secondly, the effect 
on biological behavior of cells should be examined. We here found an effect of labeling on the cell 
proliferation, but not differentiation, consistent with the fact that other investigators have demonstrated 
for instance also effects of labeling on the in vivo distribution of MSC (34,37).  
Although labeling of stem cells with MRI is promising, there are some limitations. First, more optimal 
particles are needed, that can be taken up by cells without need for potentially toxic transfection agents 
such as magnetoliposomes (44). A second problem is the dilution of the particle over time when cells 
divide. If the grafted cells continue to proliferate, this will lead to loss of signal in the majority of the 
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graft. This problem is not seen in animal models with BLI, as labeling is due to stable transduction of 
a plasmid or vector in cells (49).  
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Table1: Statistical analysis of number, size and density of inclusions in rMAPC. Cells were fixed 
and evaluated under TEM; N = number of samples. Density was measured by visual quantification 
giving number 0 (as control for unlabeled cells) till 5 (big inclusions). Data are presented as mean ± St 
error; (*) p < 0.05. 
 Resovist® Endorem® Sinerem® 
Number of inclusions 2.93* ±0.53 (n=14) 3.36* ± 0.84 (n=17) 6.35 ± 0.86 (n=20) 
Size of inclusions (µm) 1.74* ± 0.23 (n=40) 1.20 ± 0.07 (n=57) 1.46* ± 0.05 (n=127) 
Density of inclusions 2.36* ± 0.21 (n=40) 2.56* ± 0.16 (n=57) 1.05 ± 0.02 (n=127) 
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Figure legends 
Figure 1: Determination of iron content in rMAPC, mESC and mMSC. (A-C) Iron quantification 
was performed by ICP-MS. Stem cells were cultured for 24hrs with Resovist®, Endorem® or 
Sinerem®, washed with PBS twice and cultured for 1, 2 or 3 days without (U)SPIOs before iron 
quantification. (A) rMAPC, (B) mESC, (C) mMSC (n=3); p< 0.016 (*). (D-F) Number of endosomal 
inclusions over time determined by TEM. mMSC, rMAPC and mESC were labeled with Resovist®. 
The amount of inclusions per cell type was measured at time points day1, day3 and day5 after labeling 
(n=5). 
Figure 2: In vitro visualization of cells by MRI. Agar phantoms were filled with 250, 75, 15 and 5 
rMAPC, mMSC and mESC per microliter, following labeling of the cells with Endorem®, Resovist 
®or Sinerem®. (A) 3D T2*-weighted gradient-echo MRI of phantoms loaded with cells labeled for 
24hrs, followed by 24hrs culture in (U)SPIO free medium. The presence of contrast agent is illustrated 
by hypointense (dark) contrast. (B) T2-map (left) and T2*-weighted MRI (right) of Endorem® labeled 
mESC. The phantom was loaded with labeled cells at concentration of 75cells/µl cultured for an 
additional (1) 1 hr, (2) 24 hrs, (3) 48 hrs, (4) 72 hrs and (5) 120 hrs in Endorem®-free medium.  
Figure 3: Population doubling time of rMAPC, mESC and mMSC labeled with different 
(U)SPIOs. Population doubling time (PDT = T x Ln2 / Ln(A/A0), with T = time between two cell 
counts, A= the number of cells at end, A0= the initial number of cells) of cells calculated from day 0 
till day 7 after (U)SPIO labeling for the following conditions: control, Resovist®, Sinerem®, 
Endorem®. (A) mMSC, (B) mESC and (C) rMAPC (n=3); p=<0.016 (*). 
Figure 4: Comparison of phenotype of labeled and unlabeled stem cells. mMSC, rMAPC, and 
mESC were labeled with  Endorem®, Resovist®, or Sinerem®. (A-B) Two days after culture in 
(U)SPIO-free medium, RNA was extracted from rMAPC and mESC and levels of Oct-4 transcripts 
were determined by RT-qPCR. Data are shown as Delta Ct (n=3) compared with the house keeping 
gene Gapdh for (A) mESC and (B) rMAPC. (C-D) Three days after culture in (U)SPIO-free medium, 
the phenotype of mMSC and rMAPC was evaluated by FACS of cells labeled with  antibodies against 
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CD44 and c-kit (mMSC) and CD44 and CD31 (rMAPC) Isotype controls are shown in frame. FACS 
analysis plot for 1 of 3 representative experiment (C) mMSC; (D) rMAPC.  
Figure 5: Differentiation capacity of mMSC and rMAPC labeled with (U)SPIOs in comparison 
to unlabeled cells.  (A-C) mMSC labeled with Endorem®, Resovist®, or Sinerem® were allowed to 
differentiate towards osteoblasts (A-B) or  adipocytes (C). (A) Osteoblast differentiation was induced 
using osteogenic medium and progeny of labeled and unlabeled cells evaluated by 
immunohistochemistry for alkaline phosphatase staining at day 6, and calcium measurement at day 14 
(n=2). (B) Specific transcripts measured by RT-qPCR. Delta Ct-values of Bsp and Alp are shown. 
p=<0.05 (*) (C) To induce adipogenic differentiation, labeled and unlabeled cells were cultured with 
insulin, and progeny evaluated on day 21 by Oil Red O staining. Left: control, right: adipogenic 
stimulation. Fat vacuoles are formed in the cells. (D-F) rMAPC labeled with Endorem®, Resovist®, or 
Sinerem® were allowed to differentiate to hepatocyte- (D), endothelium- (E) and neuroprogenitor-like 
(F) cells as described in materials and methods. Cells were harvested and on day 21, 9 and 6, 
respectively, and expression of hepatic, endothelial and neuroprogenitor transcripts evaluated by RT-
qPCR (n=9). Delta Ct values are shown. (G-N) Evaluation of iron inclusions in differentiated rMAPC 
and mMSC by TEM. rMAPC labeled with Endorem®, Resovist®, or Sinerem®, were differentiated 
towards hepatocyte-like, endothelium-like and neuroprogenitor-like cells. On day 21, 9 and 6 
respectively, cells were evaluated for presence of iron inclusion using TEM. Labeled mMSC were 
differentiated towards osteoblasts. On day 14 cells were evaluated for presence of iron inclusions 
using TEM. (G) rMAPC liver Resovist®, (H) rMAPC liver Endorem®, (I) rMAPC endothelium 
Resovist®, (J) rMAPC Endothelium Endorem®, (K) rMAPC endothelium Sinerem®, (L) mMSC 
osteoblast Endorem®, (M) mMSC osteoblast Resovist®, (N) mMSC osteoblast Sinerem®. Iron particles 
are seen as black cluster or indicated by arrows. 
Figure 6: Determination of in vivo detectability by MR imaging. Different concentrations of 
rMAPC were labeled with Resovist®, suspended in 2l medium and were injected in the striatum of N 
OD-SCID c-/- mice. 3D T2*-weighted MR images are shown for (A) control animal (coronal and 
corresponding (dotted lines) axial view with (1) 10,000 labeled MAPC, (2) 10,000 unlabeled MAPC, 
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(3) saline injection and (4) 2µl medium + Resovist®) and (B) control animal injected with labeled 
MAPC (coronal and axial view; (1) left 10,000 cells and (2) right 50,000 cells). (C-D) GFP staining of 
cells; (C) striatum; (D) Cells engrafting along the Corpus Callosum; CC: Corpus Callosum, Cor: 
cortex, Str: striatum, ML: midline, SR: stroke region. 
Figure 7: In vivo tracking of labeled cells in the rat brain. 100,000 cells were injected in the brain 
of rats with photothrombotic lesions (left hemisphere) in the contralateral hemisphere (left). The 
panels show left: a diffusion weighted MRI to illustrate the extend of the lesion (acquired immediately 
after photothrombosis and 24 hrs before cell engraftment); middle: 3D T2*-weighted MRI acquired 24 
hrs after cell engraftment (coronal view) and on the right the corresponding axial view. The arrows 
indicate the injection sites. Images were acquired from (A) an animal with engraftment of 100,000 
Resovist® labeled mMSC (left and right hemisphere; no migration was observed); (B) an animal with 
engraftment of 100,000 unlabeled rMAPC (left and right); (C) an animal with engraftment of 100,000 
Resovist® labeled rMAPC (left and right, Note the migration of cells from the injection site towards 
the site of photothrombotic injury); (D) GFP staining of tissue slices from animal (C), and (E): 
hematoxylin-eosin staining of tissue slices from animal (C). (D) and (E): CC: Corpus Callosum, SR: 
Stroke region, Str: Striatum. 
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